Dysphonia as the Initial Symptom of Myasthenia Gravis

Chang, Chao-Hsi; Lee, Ka-Wo; Kim, Wen-Rei
January 2004
Journal of Otolaryngology;Jan/Feb2004, Vol. 33 Issue 1, p57
Academic Journal
Myasthenia gravis (MG), a chronic disease affecting all age groups, is characterized by fluctuating weakness and abnormal fatigability of skeletal muscles and an unusual prolongation of return to normal muscle strength of fatigued muscles. No other neuromuscular disorder is characterized by these two pathologic features simultaneously) Muscles innervated by cranial nerves are particularly affected by a defect related to increased cholinesterase at the neuromuscular junctions. MG is caused by a defect in neuromuscular transmission owing to an antibody mediated attack on nicotinic acetylcholine receptors at neuromuscular junctions.


Related Articles

  • Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis. Sharshar, T.; Chevret, S.; Mazighi, M.; Chillet, P.; Huberfeld, G.; Berreotta, C.; Houfani, M.; Gajdos, P. // Journal of Neurology;Apr2000, Vol. 247 Issue 4, p286 

    Valid and reliable measurements of muscle impairment are needed to assess therapeutic efficacy in patients with generalized myasthenia gravis (MG). In 22 patients we compared the validity and interobserver reliability of two scoring methods commonly used as main endpoints in clinical trials,...

  • pyridostigmine.  // Davis's Drug Guide for Nurses, 10th edition;2007, p1011 

    The article presents a guide for nurses about pyridostigmine, an antimyasthenic. Pyridostigmine is used to increase muscle strength in the symptomatic treatment of myasthenia gravis. Its pharmacokinetics, contraindication and side effects are cited. It is recommended to assess the patient for...

  • AT A GLANCE Myasthenia gravis. Dhami, Sangeeta // GP: General Practitioner;2/3/2003, p85 

    Focuses on the disease myasthenia gravis. Description of the disease; Clinical features of the disease; Treatment of the disease.

  • A hypothesis to account for the Mary Walker phenomenon. Patten, Bernard M.; Patten, B M // Annals of Internal Medicine;Mar75, Vol. 82 Issue 3, p411 

    Certain myasthenic patients show that their skeletal muscles produce a substance during ischemic exercise which, when released into the circulation, increases muscle weakness. This phenomenon has been named after Mary Walker, the physician who popularized its demonstration. It is suggested that...

  • Trials Assess Myasthenia Gravis Therapies. Hampton, Tracy // JAMA: Journal of the American Medical Association;7/4/2007, Vol. 298 Issue 1, p29 

    This article reports that efforts made to develop a therapeutic treatment for chronic autoimmune neuromuscular disorder myasthenia gravis in the United States has been modest. The article suggests that the lack in research may be caused by the knowledge that the disease is so rare. The article...

  • Myasthemia and me. Jones, LeAnna // RN;Jun76, Vol. 39 Issue 6, p50 

    Presents a case report on a patient with myasthenia gravis. Symptoms of myasthenia; Drug taken by patients with myasthenia; Adverse effects of the medicine.

  • Predictors of outcome of myasthenic crisis. Liu, Nan; Liu, Qi; Wu, Xiujuan; Liu, Kangding; Vadis, Quo // Neurological Sciences;May2015, Vol. 36 Issue 5, p801 

    No abstract available.

  • Ask 3 Questions to Strengthen Muscle Weakness Reporting in Myasthenia Gravis.  // Neurology Coding Alert;Jan2013, Vol. 15 Issue 1, pp1 

    The article presents questions and answers related to the medical coding of the intravenous drug administration for the monitoring of muscle strength in myasthenia Gravis patients including various doses administration, time spent on patient's test and additional tests for the disease.

  • Eculizumab improves fatigue in refractory generalized myasthenia gravis. Andersen, Henning; Mantegazza, Renato; Wang, Jing Jing; O'Brien, Fanny; Patra, Kaushik; Howard, James F.; Howard, James F Jr; REGAIN Study Group // Quality of Life Research;Aug2019, Vol. 28 Issue 8, p2247 

    Purpose: To evaluate the effect of eculizumab on perceived fatigue in patients with anti-acetylcholine receptor antibody-positive, refractory, generalized myasthenia gravis (MG) using the Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue subscale, and to evaluate...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics